Proteomic Profiling Change and Its Implies in the Early Mycosis Fungoides (MF)‎ Using Isobaric Tags for Relative and Absolute Quantification (iTRAQ)‎

Abstract EN

Purpose.

Mycosis fungoides (MF) is the most common T-cell lymphoma, with indolent biologic behavior in the early stage and features of invasive in the tumor stage.

The diagnosis of MF is still ambiguous and difficult.

We focused on the proteomic profiling change in the pathogenesis of early MF and identified candidate biomarkers for early diagnosis.

Methods.

We collected peripheral blood samples of MF patients and healthy individuals (HI) performed proteomic profiling analysis using isobaric tags for relative and absolute quantification (iTRAQ) platform.

Differently expressed proteins (DEPs) were filtered, and involved biological functions were analyzed through Gene Ontology (GO) and Ingenuity Pathway Analysis (IPA) software.

Results.

We identified 78 DEPs including fifty proteins were upregulated and 28 proteins were downregulated in the MF group with HI as a control.

Total DEPs were analyzed according to the biological regulation and metabolic process through GO analysis.

The pathways of LXR/RXR activation and FXR/RXR activation were significantly activated, in which APOH, CLU, and ITIH4 were involved.

The top annotated disease and function network was (Cancer, Organismal Injury and Abnormalities, Reproductive System Disease), with a key node CLU.

These DEPs were involved in cancer, including thyroid carcinoma, head and neck carcinoma, and cancer of secretory structure, in which CLU, GNAS, and PKM played an indirect role in the occurrence and development of cancer.

Relevant causal network was IL12 (family), which is related to GNAS, PKM, and other DEPs.

Conclusion.

Proteomic profiling of early-stage MF provided candidate protein biomarkers such as CLU, GNAS, and PKM, which benefit the early diagnosis and understanding of the mechanism of MF development.

Besides, lipid metabolism may be one of the pathogenesis of MF, and IL12 was a potential marker for the diagnosis and treatment of early MF.